Copyright © Inderes 2011 - present. All rights reserved.
Log in to receive notifications.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Prolight Diagnostics

0.473

 

SEK

 

-19.56 %

Less than 1K followers

PRLD

Nordic SME

Medical Equipment & Services

Health Care

Overview
Ownership
Investor consensus
-19.56%
-5.4%
+252.99%
+252.99%
+175%
+152.94%
-4.64%
-75.36%
+10%

Prolight Diagnostics develops test systems in POCT (Point of care testing). The tests are used outside of hospital laboratories to enable rapid assessments of the health of patients. The company's POCT platform is under development with the intention of measuring various biomarkers simultaneously. An important component of the work is to reduce the time for test results, particularly important for patients with heart problems. The company was founded in 1999 and is based in Lund.

Read more
Market cap
332.09M SEK
Turnover
9.66M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
30.5.
2025

Interim report Q1'25

24.6.
2025

General meeting '25

28.8.
2025

Interim report Q2'25

All
Press releases
3rd party
ShowingAll content types
Press release12 hours ago

Emergers: Equity Research | PROLIGHT: Positive results from the pre-clinical validation study de-risk the full clinical validation

Prolight Diagnostics
Regulatory press releaseyesterday

Prolight announces positive pre-clinical data

Prolight Diagnostics
Press release3/26/2025, 7:00 AM

Prolight receives notice of allowance for MicroFlex patent

Prolight Diagnostics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Press release3/13/2025, 7:00 AM

The Psyros™ Cartridge Pilot Manufacturing line achieves another milestone!

Prolight Diagnostics
Regulatory press release2/28/2025, 8:50 AM

Prolight Diagnostics publishes year-end report 2024

Prolight Diagnostics
Press release2/19/2025, 7:00 AM

Prolight receives second Notice of Intention to Grant from European Patent Office for Psyros™ technology

Prolight Diagnostics
Press release2/18/2025, 7:00 AM

Prolight receives Notice of Intention to Grant for core Psyros™ patent

Prolight Diagnostics
Press release1/20/2025, 7:00 AM

Emergers: Equity Research | PROLIGHT: SpinChip deal highlights the strategic importance and valuation potential of Prolight's solution

Prolight Diagnostics
Press release12/17/2024, 10:00 AM

Prolight Diagnostics publishes investor letter for December 2024

Prolight Diagnostics
Press release12/9/2024, 7:00 AM

Prolight strengthens IP portfolio by additional patent application

Prolight Diagnostics
Press release12/3/2024, 12:41 PM

EMERGERS VALUE PROLIGHT DIAGNOSTICS AT 730 MSEK (0,9- 1,0 SEK PER SHARE)

Prolight Diagnostics
Press release12/3/2024, 12:30 PM

Emergers: Equity Research | PROLIGHT: Commercial prototype marks an important milestone towards upcoming studies

Prolight Diagnostics
Press release12/3/2024, 7:00 AM

Prolight achieves significant milestone with arrival of first Psyros™ commercial prototype instruments

Prolight Diagnostics
Regulatory press release11/29/2024, 7:10 AM

The nomination committee appointed for the Annual General Meeting 2025.

Prolight Diagnostics
Press release11/28/2024, 7:00 AM

Emergers: Equity Research | PROLIGHT: Advancing with strengthened financials towards clinical performance study in 2025

Prolight Diagnostics
Regulatory press release11/27/2024, 7:00 AM

Prolight Diagnostics publishes quarterly report Q3, 2024

Prolight Diagnostics
Regulatory press release10/21/2024, 1:10 PM

Warrants of series TO7 were exercised to approximately 96.4 percent and Prolight Diagnostics receives approximately SEK 12.6 million

Prolight Diagnostics
Press release10/16/2024, 9:11 AM

Prolight Diagnostics: BioStock: Prolight eyes business opportunity for plasma separation method

Prolight Diagnostics
Regulatory press release10/15/2024, 6:00 AM

Last day of trading with warrants of series TO7 in Prolight Diagnostics is today, October 15, 2024

Prolight Diagnostics
Press release10/14/2024, 2:05 PM

Members of the Board of Directors, management and external investors have undertaken to exercise warrants of approximately SEK 4.3 million, corresponding to 32.9 percent of outstanding warrants of series TO7

Prolight Diagnostics
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

Privacy preferences

Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.